Bicuspid aortic valve disease by Lee, James & Otto, Catherine
76
Bicuspid aortic valve disease
AORTIC 
VALVE DISEASE
and pulmonary valves with the leaflets developing via a process 
of cavitation into three distinct layers (fibrosa, spongiosa, and 
ventricularis).(11) 
The development of the aorta is also a complex process in 
which the common truncus arteriosus is septated into the aorta 
and pulmonary arteries. Abnormalities in septation are the 
cause of common congenital heart defects such as tetraology 
of Fallot. This process is also likely related to the migration of 
cardiac neural crest cells from the pharyngeal arches and 
heart;(10) and these neuronal crest cells may be similar in origin 
to the cells involved in the development of the aortic outflow 
tract and aortic valve.(13) This common pathway may explain 
the dual involvement of abnormalities in the elastic matrix, seen 
in both the tissue of the BAV as well as the proximal ascending 
aorta.(14)
Despite a growing knowledge of the tightly regulated process 
of valve formation, the cause of the BAV syndrome remains 
unclear. A genetic basis is suggested by observations in first-
degree relatives, where the incidence of BAV is approximately 
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Aortic valve abnormalities have been recognised from the 
earliest days of medicine. Leonardo da Vinci’s notes include 
comments on the efficiency of trileaflet valve morphology and 
contain a sketch of what appears to be a bicuspid aortic valve 
(BAV).(1,2) In the 19th century, case reports and series high-
lighting BAV pathology began appearing along with suggestions 
of the now well known relationship between aortic valve 
dysfunction, endocarditis, and aortopathy.(3-5) Currently, the 
prevalence of BAV is estimated to be 0.5 - 2%(6) with a male:
female ratio of approximately 3:1. Consistent with a congen-
ital anomaly, these frequencies remain essentially unchanged 
whether evaluated in neonates,(7) children,(6) adults(8) or at 
necropsy.(9)
ETIOLOGY
Development of the heart is a complex process that begins 
with the formation of the heart tube at approximately 21 days 
post fertilisation, with completion of the mature heart at 
approximately day 50.(10-12) The cardiac outflow tract is initially 
formed by migration of cardiac neural crest cells with the 
development of a common semilunar valve. The conotruncal 
cushions form the right and left coronary leaflets of the aortic 
valve and the non-coronary leaflet forms separately from the 
right posterior intercalated cushion.(11) As the heart develops, 
the common semilunar valve is septated into the adult aortic 













9.1 - 14.6%.(15,16) Additional familial clustering is seen with 
approximately 36.7% of families having more than one relative 
with a BAV.(16) The most notable gene mutation associated 
with BAV is in NOTCH1, an autosomal dominant signaling 
and transcriptional regulator involved in valve development.(17) 
Several other genes have been associated with BAV, including 
mutations in GATA5, TGFBR1 and TGFBR2.(18,19) Likely related 
to the complexities of BAV inheritance patterns and variable 
classification schemes, a clear single gene basis for the BAV 
phenotype has not been clearly established; it is plausible that 
the BAV syndrome is actually a complex multifactorial mani-
festation of both environmental and genetic issues. 
Wide availability of rapid gene sequencing has increased interest 
in using Genome Wide Association Studies (GWAS) to eval-
uate valve disease; however the heterogeneity of the BAV 
syndrome has made primary analysis of the genetics chal-
lenging. Instead, early research has centered on the idea of 
secondary calcification of the BAV developing as a similar but 
accelerated process compared to the tricuspid aortic valve; 
and in this realm, progress has been made in the identification 
of novel loci for aortic valve and mitral annular calcification.(20,21) 
As imaging technology continues to develop, improved pheno-
typing of the BAV may improve the utility of GWAS in 
understanding its underlying genetics and pathophysiology. 
Regardless, it has become clear that further advancement will 
depend on efforts to create a targeted and planned approach 
for future studies.(22, 23) 
PHENOTYPE
One of the main challenges in identifying BAV-associated genes 
is the large number of differing phenotypic classification 
schemes.(24-28) Despite this challenge, the many prognostic 
implications of diagnosis of a BAV demand caution and meticu-
lous care in establishing a diagnosis, as even a phenotype with 
partial valve fusion may express features of the early valve 
degeneration and aortopathy (Figure 1). Although classifications 
often differ in the names given for each phenotype, most 
systems focus on leaflet morphology and include (1) orientation 
of the open leaflets or position of the commissures and (2) the 
presence or absence of a raphe. Some classifications include 
the presence and orientation of coronary arteries, although 
this information is implicit in most current classifications.(27) 
In addition to valve morphology, more complete phenotypic 
classifications also include typing of aortic dilation.(25)
In most patients, a BAV is an isolated anomaly, but can be more 
prevalent in certain conditions (Table 1). For example, in 
patients with an aortic coarctation about 50% have a BAV. 
Correspondingly, only about 5 - 10% of BAV patients have an 
aortic coarctation, but this diagnosis should still be excluded in 
this population. It is hoped that further study into these special 
populations may provide further information regarding the 
etiology and development of the BAV syndrome. 
LEAFLET MORPHOLOGY
Transthoracic echocardiography (TTE) is the standard approach 
for evaluation of leaflet morphology due to widespread avail-
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FIGURE 1: Transthoracic echocardiographic findings in a 19-year-old patient on the spectrum of the bicuspid aortic valve 
syndrome. A. Short axis of the aortic valve demonstrating partial fusion of the base of the right and left coronary cusps (yellow arrow). 
B. Colour Doppler in the parasternal long axis showing mild aortic regurgitation. C. Parasternal view of the proximal ascending aorta with a 
mild dilation of the ascending aorta but normal aortic sinuses and sinotubular junction. 








ability, low cost and lack of ionising radiation. The imaging diag-
nosis of a BAV can be challenging as off axis acquisitions of 
a normal trileaflet aortic valve may be easily mistaken for a 
bicuspid valve. Conversely, a bicuspid valve may be mistaken 
for a trileaflet valve in diastole, especially if a raphe is present. 
A correct diagnosis relies on visualisation of the open leaflets in 
systole, with 2 distinct commissures. We recommend describing 
(1) leaflet orientation, (2) the presence or absence of a raphe, 
(3) coronary artery ostia locations and (4) a qualitative assess-
ment of valve calcification or thickening (Figure 2). The pheno-
typic description we recommend is:
 ■ Type 1 with congenital “fusion” of the right and left cusps 
resulting in a larger anterior/rightward leaflet with both 
coronaries arising from this sinus.
 ■ Type 2 with congenital “fusion” of the right and non-
coronary cusps, with the coronary ostia arising from 
separate sinuses. 
 ■ Type 3 with congenital “fusion” of the left and non-coronary 
cusps, with the coronary ostia arising from separate sinuses. 
AORTIC VALVE DISEASE
Although rarely needed, better visualisation of valve anatomy 
can be obtained with transesophageal echocardiography, cardiac 
magnetic resonance imaging (MRI) or gated computed tomog-
raphy (CT). 
Other variants of congenitally abnormal aortic valves may 
be mistaken for a BAV (Figure 3). This occurs most often with 
a unicuspid valve which has a single commissure, a single leaflet 
and a characteristic teardrop-shaped or round opening. Patients 
with unicuspid aortic valves typically present with aortic stenosis 
(AS) at a much earlier age than patients with a BAV.
VALVE HEMODYNAMICS
Evaluation of AS and aortic regurgitation (AR) is essential in 
evaluation of the BAV patient. Standard measures of AS 
severity include an echocardiographic assessment of maximum 
aortic jet velocity, mean transaortic pressure gradient and 
continuity equation valve area (Figure 4). AR is evaluated per 
guidelines based on colour Doppler vena contracta width, the 
continuous wave Doppler velocity curve, and evidence for 
holodiastolic flow reversal in the thoracic and abdominal 
aorta. Quantitative measures of left ventricle (LV) size and 
systolic function are also essential when regurgitation is 
present. MRI can provide more quantitative measures of 
AR severity as well as accurate assessments of LV size and 
function if needed (Figure 5).
















84 - 89%(51, 52)
39 - 47%(53,54)
14 - 30%(56-58)
5 - 11%(55, 59)
Notes
 
Large variability due in part 
due to heterogeneous 
reporting and nomenclature
Subaortic stenosis 
predisposes to valve damage 
leading to aortic regurgitation
Recurrence of subaortic 
stenosis after resection is 
common (20%)
BAV was not initially 
described as part of the 
Shone complex
Frequent structural 
abnormalities of aortic valve 
are present(55)
95% show R-L cusp fusion
High prevalence of both 
ascending aortic dilation and 
aortic coarctation
Other common valvular 
pathology in Williams 
syndrome include supravalvar 
aortic stenosis, peripheral 
pulmonary stenosis, mitral 
valve prolapse, mitral 
regurgitation and supravalvar 
pulmonary stenosis(55)
FIGURE 2:  Bicuspid aortic valve (BAV) classifi cation 
and prevalence of each morphology. Each schematic 
diagram shows the 3 aortic sinuses with the left and right 
coronary ostia. Leafl et opening and the presence of a raphe 
between “fused” leafl ets is shown by the red lines. The percent 
of BAV patients with each valve type from the study by Schafer, 
et al.(25) is shown. Type 1 BAV, with congenital fusion of the right 
and left coronary cusps (both coronaries originate from the 
same anterior/rightward larger cusp) occurs in about 80% of 
BAV patients. Type 2 BAV, with fusion of the right and non-
coronary cusps is present in about 20% of patients with the 
coronaries arising from separate cusps. Type 3 BAV is rare. 
























Dilation of the aortia is common in BAV patients, even with 
normal valve function.(29) Evidence that intrinsic structural 
abnormalities underlie the valvular pathology of BAV is seen in 
pathologic specimens that show increased extracellular matrix 
production, tissue disorganisation and valvular interstitial cell 
disruption.(12) By the time patients reach the age of 50 - 60, 
91% are found to have some degree of aortic dilation.(30) 
Variation exists in the aortic shape and regions of dilation, 
which may involve the sinuses of Valsalva, ascending aorta, or 
both (Figure 6). The rate of progression of aortic dilation does 
not appear to be related to the severity of associated AS or 
AR.(29,31,32) In a study of 353 BAV patients followed for an 
average of 3.5 years, 43% had no evidence of progressive 
aortic dilation; and in those with progressive dilation, the rate 
of change averaged 0.42mm/year with a wide variation in 
the yearly rate of change among patients.(33) 
The underlying cause of the association between the BAV and 
aortic dilation is unclear. While the theories of common 
structural abnormalities are popular, the cystic medial degen-
FIGURE 3: Unicupsid aortic valve. A. Parasternal long axis showing the domed shape of a unicuspid aortic valve in systole. B. Corresponding 
short axis view demonstrating the round shape of a unicuspid aortic valve in short axis. Imaging illustrates the challenge of visualising most 
stenotic portion of leaflet tips. 
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FIGURE 4: Bicuspid aortic valve stenosis. A. Continuous wave Doppler indicates a peak velocity of 4.1m/s consistent with severe aortic 
stenosis. B. Transesophageal echocardiogram (TEE) image of a bicuspid aortic valve (BAV) in short axis. C. Colour Doppler with aliasing 
through BAV leaflet tips. D. ECG-gated computed tomography (CT) scan shows aortic valve in short axis and illustrates the benefit of CT 
for evaluation of valve morphology if not well seen on an echocardiogram. 







eration is not universally seen in all patients with BAV and 
aortopathy. Abnormal flow patterns from the BAV have also 
been suspected as the underlying mechanism of aortopathy. 
Flow patterns as visualised with 4D flow MRI may give new 
insights into this theory, but a definite cause-effect relationship 
has not been established. Most likely, the etiology of the 
aortopathy with BAV is more complex and multifactorial in 
nature.(34-36)
CLINICAL OUTCOMES 
In patients with the BAV syndrome, age, severity of AS and AR 
are independently associated with primary cardiac events. 
Despite this, asymptomatic patients with BAV with minimal or 
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no hemodynamic abnormalities enjoy excellent long-term 
survival(37) (Figure 7). In a series of 642 BAV patients, 25% had 
a cardiac event within 10 years of follow-up; and most of 
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FIGURE 5: Bicuspid aortic valve regurgitation. Magnetic resonance imaging (MRI) shows (A) a short axis view of the bicuspid valve in 
systole (B) a long axis view in diastole showing the regurgitant jet (arrow). As with colour Doppler, the jet itself is not accurate for determining 
severity of regurgitation. (C) A MRI derived flow curve in the ascending aorta demonstrates forward flow in systole and reverse flow in 
diastole due to AR. This approach allows accurate quantitation of regurgitant volume and fraction. 
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FIGURE 6: Aortic dilation associated with bicuspid aortic valve disease. A. Computed tomography angiography (CTA) of normal 
aorta. B. Magnetic resonance angiography (MRA) of isolated dilation of aortic sinuses. C. MRA showing aorta with dilation limited to the 
proximal ascending portion. D. CTA of an aorta that is dilated through the aortic arch. 
TABLE 11: Long term clinical outcomes in patients >50 
years of age.
Outcome Frequency 
Overall survival (at 15 years) 40 - 78%
Aortic valve surgery ~100%
Endocarditis 1 - 4%
Ascending aortic aneurysm (>5.0cm) 3 - 10%













these events were aortic valve replacement for AS or AR 
(22%), with aortic complications in only 2%, cardiac death in 
3% and heart failure in 2%. Predictors of adverse outcomes 
over this time period included older age, more severe AS or 
AR, and more severe valve thickening and calcification.(37,38) 
Over the lifetime of BAV patients, nearly all eventually will 
require AVR for stenosis and/or regurgitation (Table II). 
AORTIC STENOSIS
The most common outcome in adults with a BAV is severe 
AS due to progressive leaflet thickening and calcification.(26) 
In patients undergoing aortic valve replacement (AVR) for AS, 
over 50% have a BAV. A BAV is the cause of AS requiring 
AVR in 60% of patients under age 70 years but also accounts 
for 40% of cases in those over age of 70.(39) The average age at 
symptom onset in patients with severe AS due to a BAV is 
younger (about age 60 - 70 years) than in patients with a 
trileaflet aortic valve (typically age 70 - 90 years). At the tissue 
level, both age groups do appear to share the same 
pathophysiology.(40) 
AORTIC REGURGITATION
Although most patients with a BAV have some degree of AR,(41) 
severe AR leading to progressive LV dilation, symptoms and 
the need for AVR is less common, probably occurring in 10 - 
20% of BAV patients. Clinical outcomes with AR due to a 
BAV are reflected in data on the natural history of chronic 
AR.(42) AVR for significant AR due to a BAV typically occurs in 
young adulthood (age <40 years) and is unlikely in older BAV 
patients, although is still periodically required in the cases of 
infective endocarditis. 
AORTIC DISSECTION
Aortic dilation is common in BAV patients, with a risk of aortic 
dissection that is 5 - 10 times higher than in the general 
population. However, a recent study showed an overall low 
rate of aortic dissection over 16 years of follow-up, with an 
incidence of aortic dissection of only of 3.1 (95% CI, 0.5 - 9.5) 
cases per 10 000 patient-years.(43) Less than 10% of all aortic 
dissections occur in patients younger than 40 years of age; and 
in this younger age group, common causes of dissection are 
Marfan syndrome, hypertension and familial aneurysm; with less 
than 10% having a BAV. In patients over age 40 years with 
aortic dissection, BAV is rare.(44) In patients who have undergone 
AVR, however, the presence of a BAV is a risk factor for 
subsequent dissection, particularly in those with an aortic 
diameter greater than 4.5cm. 
ENDOCARDITIS
The endocarditis risk of BAV is elevated compared to the 
general population with a long-term risk of approximately 2 - 
3%. Antibiotics at the time of dental procedures are not 
currently recommended, and the prevention of endocarditis 
relies on optimal dental care and oral health, along with patient 




There is no medical therapy known to change the clinical course 
of BAV disease. Instead, management is centered on early 
diagnosis, monitoring of disease progression to determine 
optimal timing of intervention, treatment of concurrent con-
FIGURE 7: Long term outcomes with bicuspid aortic 
valve disease. The frequency of primary cardiac events in 
patients with more than 1 risk factor at baseline (n=142) was 
65% (SD, 5%); in all participants (n=642), 25% (SD, 2%); in patients 
with 1 risk factor at baseline (n=306), 18% (SD, 3%); and in 
patients with no risk factors at baseline (n=194), 6% (SD, 2%). 
The risk factors for primary cardiac events were age older than 
30 years, moderate or severe aortic regurgitation, and moderate 
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FIGURE 8: Overview of the basic management of a bicuspid aortic valve disease. The primary outcomes of stenosis, regurgitation 
and aortic dilation determine the timing of periodic imaging and clinical evaluation as well as timing of optimal intervention. However, even 
patients with normal valve function benefi t from preventative care. Patients in all groups should receive education about the expected 
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Guideline based decision 
for intervention
ditions (such as hypertension), and primary prevention of ather-
osclerotic coronary disease (Figure 8). Although the process of 
valve calcification at the tissue level is similar to atherosclerosis, 
there is no convincing evidence that lipid-lowering treatment 
alters the disease course. However, patients should have 
standard risk factor evaluation and treatment based on current 
guidelines for primary prevention of cardiovascular disease. 
Treatment of hypertension follows standard guidelines with no 
evidence to support use of beta-blockers or other therapies 
in normotensive patients with a BAV. 
Periodic Imaging
After the initial diagnosis of BAV, the timing of periodic imaging 
is based on the degree of valve dysfunction and the presence of 
aortic dilation. In younger patients with a normally functioning 
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BAV and normal aortic dimensions, intermittent re-evaluation 
in 3 - 5 years intervals is appropriate. When AS or AR is present, 
timing of follow-up is based on the severity and rate of pro-
gression of the valve dysfunction (Figure 8).
If well visualised, evaluation and follow up of the proximal aorta 
should be performed with TTE. In patients with no family 
history of aortic dissection; and if the aortic sinuses, sinotubular 
junction and ascending aorta are well visualised and normal in 
size; further imaging is not needed. If the aorta is not well 
visualised, is significantly dilated, or there is a family history of 
aortic dilation or dissection, additional imaging of the aorta 
with CT or MRI is recommended. The interval of repeat 














With all aortic imaging modalities, it is important to understand 
the sources of potential measurement variability between 
studies and within different modalities. On echocardiography, 
aortic diameter is measured at end-diastole from the black-
white interface of the inner edges of the aortic lumen. However, 
CT and MRI measurements typically include the thickness of 
the aortic walls, usually adding about 2mm compared to the 
echocardiographic measurements. CT and MRI measurements 
are ideally made on dedicated 3D workstations where the 
aorta can be measured in double oblique views at the widest 
region of dilation (Figure 9). Major management decisions 
should take these differences into account. 
TIMING AND METHOD OF INTERVENTION
The timing of intervention for BAV disease follows standard 
guidelines for management of AS, AR and aortic dilation. The 
major indications for AVR in BAV patients are severe 
FIGURE 9: Measurement of aortic size. A-B. Dilated proximal ascending aorta being measured in 2 double oblique planes through the 
proximal ascending aorta. The two purple lines create a double oblique plane through the true cross section of the aorta seen in panel C. This 
contrasts with panel D where the aorta in same region is seen in the true radiologic axial plane, which obliquely cuts the aorta leading to a 
falsely elongated appearance. An understanding of the underlying measurement methodology is important to avoid making clinical decisions 






symptomatic AS or AR, severe AR or AS with LV systolic 
dysfunction and progressive LV dilation with severe AR. 
Surgical aortic valve replacement (SAVR) has long been the 
standard of care for BAV patients with excellent and durable 
results. As patients with BAV often are younger and may 
require aortic root replacement at the time of valve surgery, 
SAVR remains the preferred strategy. Although a BAV initially 
was considered a contraindication in the early clinical trials for 
transcatheter aortic valve implantation (TAVI), recent data 
suggests that TAVI is effective for treatment of severe AS due 
to a BAV. Thus, in older adults with normal aortic dimensions, 
current guidelines for TAVI are appropriate whether AS is due 
to a trileaflet or bicuspid valve. 
Aortic root replacement is indicated for an aortic diameter 
over 5.5cm but may be considered with a diameter of 5.0cm if 
there is evidence for rapid progression, a strong family history 
or other considerations. The optimal timing of aortic root 
replacement is when the annual risk of aortic dissection is 
greater than the risk of the surgical procedure; thus the timing 
for surgery vs periodic monitoring can be dependent on 
individual patient risk factors. In patients undergoing AVR, 
concurrent replacement of the aortic root is recommended if 
aortic diameter is over 4.5cm to prevent subsequent dissection. 
The specific surgical approach depends on the pattern of aortic 
dilation. If the sinuses are normal and dilation is isolated to the 
ascending aorta, an interposition graft replacement of the 
ascending aorta is the simplest approach. If dilation involves the 
aortic sinuses, a Bentall procedure with coronary reimplantation 
and a prosthetic aortic valve may be necessary. Some centres 
perform reimplanatation of the native BAV (the David pro-
cedure) although only limited long-term outcome data for this 
procedure in BAV patients is available.(45)
FUTURE DIRECTIONS
Despite advances in the understanding and management of 
patients with a BAV, many unknowns remain. We continue to 
lack a robust understanding of the embryologic and genetic 
underpinnings of the BAV syndrome and its variants. As no 
effective disease modifying medical therapies have been identi-
fied for the BAV syndrome, management relies on monitoring 
and appropriately timed surgical intervention. However, better 
risk prediction models are needed to guide intervention as only 
a subset of BAV patients has progressive aortic dilation or aortic 
dissection. BAV patients offer an ideal opportunity for pre-
vention of disease progression as imaging allows for diagnosis 
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early in life. If basic research can identify therapeutic targets, 
perhaps in the future, prevention of leaflet calcification or aortic 
dilation will be possible. Finally, as TAVI continues to be refined, 
it may offer improved options for mechanical intervention in 
BAV patients with valve dysfunction.(46)
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